DDIT3 and mantle cell lymphoma: To achieve adequate statistical power, we pooled and analyzed the long-term follow-up data of all MCL patients treated within the GLSG1996 and GLSG2000 trials with CHOP and R-CHOP to more reliably estimate treatment effects by the addition of rituximab to CHOP with a focus on OS and relevant subgroups.